{"id":"https://openalex.org/W4231289309","doi":"https://doi.org/10.1016/j.jval.2015.09.2660","title":"Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study","display_name":"Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study","publication_year":2015,"publication_date":"2015-10-20","ids":{"openalex":"https://openalex.org/W4231289309","doi":"https://doi.org/10.1016/j.jval.2015.09.2660"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2015.09.2660","doi":"https://doi.org/10.1016/j.jval.2015.09.2660","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2015.09.2660","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301515047361/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.valueinhealthjournal.com/article/S1098301515047361/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018678002","display_name":"Paul Emery","orcid":"https://orcid.org/0000-0002-7429-8482","observed_orcids":["https://orcid.org/0000-0002-7429-8482","https://orcid.org/0000-0002-4136-3436"]},"institutions":[{"id":"https://openalex.org/I130828816","display_name":"University of Leeds","ror":"https://ror.org/024mrxd33","country_code":"GB","type":"education","lineage":["https://openalex.org/I130828816"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P Emery","raw_affiliation_strings":["Leeds University, Leeds, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leeds University, Leeds, UK","institution_ids":["https://openalex.org/I130828816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112075980","display_name":"C.O. Bingham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C Bingham","raw_affiliation_strings":["Johns Hopkins University, Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johns Hopkins University, Baltimore, MD, USA","institution_ids":["https://openalex.org/I145311948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059846084","display_name":"G Burmester","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G Burmester","raw_affiliation_strings":["Universit\u00e4tsmedizin Berlin, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e4tsmedizin Berlin, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085126399","display_name":"VIVIEN P. BYKERK","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1281539108","display_name":"Hospital for Special Surgery","ror":"https://ror.org/03zjqec80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1281539108"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V Bykerk","raw_affiliation_strings":["Hospital for Special Surgery, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital for Special Surgery, New York, NY, USA","institution_ids":["https://openalex.org/I1281539108"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059206584","display_name":"Daniel E. Furst","orcid":"https://orcid.org/0000-0001-7857-2373","observed_orcids":["https://orcid.org/0000-0001-7857-2373","https://orcid.org/0000-0002-4018-7629"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D Furst","raw_affiliation_strings":["UCLA, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107872282","display_name":"Xavier Mariette A","orcid":"https://orcid.org/0000-0002-4244-5417","observed_orcids":["https://orcid.org/0000-0002-4244-5417"]},"institutions":[{"id":"https://openalex.org/I102197404","display_name":"Universit\u00e9 Paris-Sud","ror":"https://ror.org/028rypz17","country_code":"FR","type":"education","lineage":["https://openalex.org/I102197404","https://openalex.org/I277688954"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"X Mariette","raw_affiliation_strings":["Paris-Sud University, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Paris-Sud University, Paris, France","institution_ids":["https://openalex.org/I102197404"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110572498","display_name":"O. Purcaru","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"O Purcaru","raw_affiliation_strings":["UCB Pharma, Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Brussels, Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014366521","display_name":"G. Coteur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"G Coteur","raw_affiliation_strings":["UCB Pharma, Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Brussels, Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011958667","display_name":"Brenda Vanlunen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B Vanlunen","raw_affiliation_strings":["UCB Pharma, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Durham, NC, USA","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047117557","display_name":"Michael E. Weinblatt","orcid":"https://orcid.org/0000-0001-5215-5512","observed_orcids":["https://orcid.org/0000-0001-5215-5512"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M Weinblatt","raw_affiliation_strings":["Brigham and Women\u2019s Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women\u2019s Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":0.5529,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":{"value":0.72532925,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"18","issue":"7","first_page":"A707","last_page":"A708"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9692000150680542,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9692000150680542,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.02669999934732914,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/certolizumab-pegol","display_name":"certolizumab pegol","score":0.9959999918937683},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.9070000052452087},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9810000061988831},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.781000018119812},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.4860000014305115},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.49399998784065247},{"id":"https://openalex.org/keywords/early-rheumatoid-arthritis","display_name":"early rheumatoid arthritis","score":0.6380000114440918},{"id":"https://openalex.org/keywords/cost-utility-analysis","display_name":"cost-utility analysis","score":0.7210000157356262},{"id":"https://openalex.org/keywords/depressive-disorders","display_name":"depressive disorders","score":0.7289999723434448}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9317207336425781},{"id":"https://openalex.org/C2776215756","wikidata":"https://www.wikidata.org/wiki/Q412909","display_name":"Certolizumab pegol","level":4,"score":0.9066586494445801},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.7696207761764526},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6939770579338074},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4970116913318634},{"id":"https://openalex.org/C2909065710","wikidata":"https://www.wikidata.org/wiki/Q266423","display_name":"Bristol-Myers","level":2,"score":0.474852591753006},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.462507426738739},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.45396503806114197},{"id":"https://openalex.org/C58041806","wikidata":"https://www.wikidata.org/wiki/Q1660484","display_name":"Imputation (statistics)","level":3,"score":0.44224268198013306},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4304201900959015},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4209122061729431},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.36765313148498535},{"id":"https://openalex.org/C9357733","wikidata":"https://www.wikidata.org/wiki/Q6878417","display_name":"Missing data","level":2,"score":0.06664818525314331},{"id":"https://openalex.org/C119857082","wikidata":"https://www.wikidata.org/wiki/Q2539","display_name":"Machine learning","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2015.09.2660","doi":"https://doi.org/10.1016/j.jval.2015.09.2660","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2015.09.2660","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301515047361/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2015.09.2660","doi":"https://doi.org/10.1016/j.jval.2015.09.2660","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2015.09.2660","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301515047361/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4231289309.pdf","grobid_xml":"https://content.openalex.org/works/W4231289309.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2415233973","https://openalex.org/W2338736527","https://openalex.org/W2164024605","https://openalex.org/W6904727306","https://openalex.org/W4242865522","https://openalex.org/W7017977860","https://openalex.org/W98992753","https://openalex.org/W2810918621","https://openalex.org/W2258404915","https://openalex.org/W2146550202"],"abstract_inverted_index":null,"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2022-05-12T00:00:00"}